Combinations of HDAC inhibitors with anti-PD-L1 agents have been shown to synergistically reduce melanoma cell survival, due to HDAC inhibitors' ability to induce prolonged PD-L1 expression in both human and mouse melanoma cell lines [93, 94]. The gene discussed is HDAC9; the disease is melanoma.